Related Experiment Video

Updated: Feb 17, 2026

Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter
07:53

Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter

Published on: June 16, 2022

3.9K

Sodium tanshinone IIA sulfate adjunct therapy reduces high-sensitivity C-reactive protein level in coronary artery

Siming Li1, Yang Jiao1,2, Hanjay Wang3

  • 1Cardiovascular Diseases Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.

Scientific Reports
|December 14, 2017
PubMed

Insights

Sodium tanshinone IIA sulfate (STS) effectively reduced high-sensitivity C-reactive protein (hs-CRP) and inflammation markers in coronary artery disease (CAD) patients. This adjunct therapy improved angina symptoms and offers a potential new treatment for cardiovascular inflammation.

Area of Science:

  • Cardiology
  • Pharmacology
  • Inflammation Research

Background:

  • High-sensitivity C-reactive protein (hs-CRP) is a key marker for cardiovascular events in coronary artery disease (CAD).
  • Reducing hs-CRP levels may offer additional benefits for CAD patients.

Purpose of the Study:

  • To evaluate the effectiveness of adjunct sodium tanshinone IIA sulfate (STS) therapy in reducing inflammation markers in CAD patients.
  • To assess the impact of STS on hs-CRP levels and angina symptoms.

Main Methods:

  • A parallel-design, randomized-controlled trial was conducted.
  • Patients with unstable angina or non-ST-elevation myocardial infarction and elevated hs-CRP were randomized.
  • The experimental group received standard therapy plus STS injection (80 mg daily for 14 days), while the control group received standard therapy alone.

Main Results:

  • The STS group showed significantly lower hs-CRP levels post-treatment (1.72 vs 3.20 mg/L, p=0.0191).
  • Adjunct STS therapy also reduced levels of interleukin-6, monocyte chemotactic protein-1 (MCP-1), and soluble CD40 ligand.
  • Improved angina symptom control and sustained lower MCP-1 levels were observed in the STS group post-treatment.

Conclusions:

  • Adjunct STS therapy, combined with standard medical care, effectively reduces elevated hs-CRP and other circulating inflammation markers in CAD patients.
  • STS demonstrates potential as an adjunctive treatment to improve inflammatory profiles and clinical outcomes in CAD.

More Related Videos

Author Spotlight: Treating Knee Osteoarthritis with Tuina - A New Perspective06:14

Author Spotlight: Treating Knee Osteoarthritis with Tuina - A New Perspective

Published on: January 12, 2024

2.8K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
459
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
309
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
294
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.6K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
307